tiprankstipranks
Trending News
More News >
Repare Therapeutics Inc (RPTX)
:RPTX
US Market
Advertisement

Repare Therapeutics (RPTX) Stock Statistics & Valuation Metrics

Compare
433 Followers

Total Valuation

Repare Therapeutics has a market cap or net worth of $66.59M. The enterprise value is -$49.16M.
Market Cap$66.59M
Enterprise Value-$49.16M

Share Statistics

Repare Therapeutics has 42,959,170 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding42,959,170
Owned by Insiders1.45%
Owned by Institutions56.57%

Financial Efficiency

Repare Therapeutics’s return on equity (ROE) is -0.56 and return on invested capital (ROIC) is -62.16%.
Return on Equity (ROE)-0.56
Return on Assets (ROA)-0.48
Return on Invested Capital (ROIC)-62.16%
Return on Capital Employed (ROCE)-0.62
Revenue Per Employee414.55K
Profits Per Employee-656.50K
Employee Count129
Asset Turnover0.30
Inventory Turnover0.00

Valuation Ratios

The current PE Ratio of Repare Therapeutics is ―. Repare Therapeutics’s PEG ratio is ―.
PE Ratio
PS Ratio
PB Ratio
Price to Fair Value0.37
Price to FCF
Price to Operating Cash Flow-0.65
PEG Ratio

Income Statement

In the last 12 months, Repare Therapeutics had revenue of 53.48M and earned -84.69M in profits. Earnings per share was -2.00.
Revenue53.48M
Gross Profit40.10M
Operating Income-93.52M
Pretax Income-83.25M
Net Income-84.69M
EBITDA-90.22M
Earnings Per Share (EPS)-2.00

Cash Flow

In the last 12 months, operating cash flow was -103.34M and capital expenditures 0.00, giving a free cash flow of -103.34M billion.
Operating Cash Flow-103.34M
Free Cash Flow-103.34M
Free Cash Flow per Share-2.41

Dividends & Yields

Repare Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta1.27
52-Week Price Change-49.68%
50-Day Moving Average1.50
200-Day Moving Average1.60
Relative Strength Index (RSI)59.69
Average Volume (3m)493.26K

Important Dates

Repare Therapeutics upcoming earnings date is Nov 5, 2025, After Close (Confirmed).
Last Earnings DateAug 8, 2025
Next Earnings DateNov 5, 2025
Ex-Dividend Date

Financial Position

Repare Therapeutics as a current ratio of 6.77, with Debt / Equity ratio of 0.59%
Current Ratio6.77
Quick Ratio6.77
Debt to Market Cap0.00
Net Debt to EBITDA0.92
Interest Coverage Ratio0.00

Taxes

In the past 12 months, Repare Therapeutics has paid 1.44M in taxes.
Income Tax1.44M
Effective Tax Rate-0.02

Enterprise Valuation

Repare Therapeutics EV to EBITDA ratio is 0.30, with an EV/FCF ratio of 0.36.
EV to Sales-0.51
EV to EBITDA0.30
EV to Free Cash Flow0.36
EV to Operating Cash Flow0.36

Balance Sheet

Repare Therapeutics has $109.47M in cash and marketable securities with $649.00K in debt, giving a net cash position of -$108.82M billion.
Cash & Marketable Securities$109.47M
Total Debt$649.00K
Net Cash-$108.82M
Net Cash Per Share-$2.53
Tangible Book Value Per Share$3.56

Margins

Gross margin is 72.05%, with operating margin of -174.88%, and net profit margin of -158.37%.
Gross Margin72.05%
Operating Margin-174.88%
Pretax Margin-155.67%
Net Profit Margin-158.37%
EBITDA Margin-168.71%
EBIT Margin-172.31%

Analyst Forecast

The average price target for Repare Therapeutics is $1.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$1.50
Price Target Upside-5.66% Downside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast-99.64%
EPS Growth Forecast-59.17%

Scores

Smart Score2
AI Score60
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis